Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. - Chanchlani, Neil; Lin, Simeng; Chee, Desmond; Hamilton, Benjamin; Nice, Rachel; Arkir, Zehra; Bewshea, Claire; Cipriano, Bessie; Derikx, Lauranne A A P; Dunlop, Allan; Greathead, Louise; Griffiths, Rachel L; et al. (Journal of Crohn's & Colitis, 2022)